Physician profile
Mariah Cheevers
NPI 1205467677
$1,583.63
in general payments reported to CMS, 2019-2025
22 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $714 · 2023: $255 · 2024: $490 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $869.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $366.65 | 2022-2024 | Breztri, Airsupra, Fasenra |
| Novo Nordisk INC | $262.19 | 2022-2025 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $150.92 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $139.29 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.34 | 2022 | |
| Ironshore Pharmaceuticals INC. | $89.08 | 2024 | |
| Glaxosmithkline, LLC. | $69.98 | 2023-2025 | Bexsero, Trelegy Ellipta, Pediarix |
| Pfizer INC. | $61.55 | 2022-2025 | |
| Lilly USA, LLC | $49.42 | 2022-2025 | Mounjaro, Zepbound |
| Boston Scientific Corporation | $40.11 | 2024 | Wavewriter Alpha Prime 16 |
| Otsuka America Pharmaceutical, INC. | $37.54 | 2022-2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $29.62 | 2022 | |
| Verrica Pharmaceuticals INC. | $23.48 | 2024 | Ycanth |
| Inspire Medical Systems, INC. | $22.86 | 2024 | Inspire |
| Amgen INC. | $20.38 | 2025 | Otezla, Repatha |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $19.15 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.92 | 2025 | Caplyta |
| Corium, LLC | $17.77 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.89 | 2023 | |
| Dexcom, INC. | $14.45 | 2024 | Dexcom G6 Transmitter |
| Agile Therapeutics, INC. | $14.31 | 2022 | |
| Merck Sharp & Dohme LLC | $13.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariah Cheevers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.